(Q46693880)

24 December 2017

title

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia (English)

1 reference

24 December 2017

0 references

1 reference

1 reference

Gao H

1

1 reference

24 December 2017

Lee BN

2

1 reference

24 December 2017

Talpaz M

3

1 reference

24 December 2017

Donato NJ

4

1 reference

24 December 2017

Cortes JE

5

1 reference

24 December 2017

Kantarjian HM

6

1 reference

24 December 2017

Reuben JM

7

1 reference

24 December 2017

publication date

1 November 2005

1 reference

24 December 2017

published in

Leukemia

1 reference

24 December 2017

volume

19

1 reference

24 December 2017

page(s)

1905-1911

1 reference

24 December 2017

issue

11

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403933

exact match

0 references

cites work

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

Chronic myeloid leukemia: current treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

Evidence for differential intracellular signaling via CD4 and CD8 molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

Two distinct mechanisms of cytotoxicity mediated by herpes simplex virus-specific CD4+ human cytotoxic T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

7 January 2021

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

7 January 2021

Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

7 January 2021

Molecular characterization of the putative T-cell receptor cavity of the superantigen staphylococcal enterotoxin B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

7 January 2021

Distinct roles for CD4 and CD8 as co-receptors in antigen receptor signalling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

7 January 2021

Distinct roles for CD4 and CD8 as co-receptors in T cell receptor signalling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

7 January 2021

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

7 January 2021

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403933

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403933

1 reference

24 December 2017

PubMed ID

16151467

1 reference

24 December 2017